biotechbeta (@biotechbeta) profile picture

Nowadays people know the price of everything, and the value of nothing.

Joined September 2021
Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)
$REPL trading like there's a leak
1
5
1,760
$FBRX who remembers the atopic dermatitis days from 5 years ago? - what a pivot
361
(9/n) $ABVX Abstract #9 (surprise: it's safe)
1
1
13
5,965
$ABVX this ecco abstract shows the prostate cancer stage 1 from induction trial. ABTECT is a rerandomized responder design, so a patient flows from induction into maintenance. A stage I prostate detected during induction belongs to a pt who then continued into maintenance on 50
4
2
1
21
2,991
correct me if im wrong but this has gotta be the same prostate patient ... ? same one from induction into maintenance on 50mg $abvx
1
1
17
1,030
$ABVX for anyone confused / wondering what to think 50mg at w96 and w144 = NO NEW safety signals, no breast/prostate/NMSCs... obe won't just cause cancer within 60 days we'll be ok
2
1
26
3,015
If obe were driving oncogenesis you would expect 25mg to sit somewhere between placebo/50 mg...second, organ scatter - real carcinogens concentrate. The JAK class black box was established in a 4,362-patient dedicated trial (lung NHL), not from five lineages appearing once $ABVX
5
21
3,240
$ABVX The colonic dysplasia is especially telling too - dysplasia is precancerous, UC pts undergo surveillance c-scopy, and protocol required baseline endoscopy. A dysplastic focus found 60 days into dosing was almost certainly present already. same applies to prostate &breast
9
769
$ABVX Prostate cancers double roughly every 2–4 years, and prostate cancer is extraordinarily common as occult/latent disease in this demographic ... Bell et al. found histologic prostate cancer in 21% of men across all ages
6
542
$ABVX if there was clustering , I'd sell. but there isn't. instead you have high incidence cancers. breast at a 200-day doubling time needs 20 years to reach 1–2 cm; even an aggressive 100-day doubling time needs 10 years & a remarkably fast 20day doubling tumor still needs 2yrs
1
8
683
$ABVX also if PI caught cancer within 60 day latency -- highly likely they were just present but undiagnosed at enrollment Looking beyond JAKs, S1P modulators etrasimod (Velsipity) and ozanimod (Zeposia) carry no boxed warning; cutaneous malignancy is mere Warnings/Precaution
10
829
"the randomized controlled trial at the end of the randomization period found no benefit" - Makary Makary literally said randomized twice -- its not $RGNX open trial $QURE
2
2
1,036
(25/25) $ABVX Takeaways 3. Do NOT see this as an academic exercise. It's a positioning campaign + laying the railway tracks for commercialization. Every discount pathway is closed now =higher buyout price commanded. FFS might BTC my 220 calls now /fin and happy lunar new year!
2
23
3,374
(24/n) $ABVX TAKEAWAYS 2. reframing obe as more than an anti-inflammatory.. the fibrosis abstract is HUGE - If miR-124 modulation shows anti-fibrotic signal in IBD models, they’re hinting at disease mod. In Crohn’s especially, fibrosis = unmet need + surgical burden = higherSP
2
1
28
4,352
jjaf231.030 --> Inhibition of fibroblast activation and reduced collagen deposition in IBD models via miR-124 modulation. If this translates, the narrative shifts from inflammation control (UC) to potential disease modification... woah
6
874
(23/n) $ABVX Early look at all 22 abstracts, big takeaways below: 1. $ABVX carpet bombed ECCO for good reason, they are building a totality-of-evidence fortress around obefazimod in UC with every angle: subgroups, duration, biomarkers...its for regulatory and payer fasttracking
1
38
5,507
(22/n) $ABVX Abstract #22 (last one)
1
9
2,603
(21/n) $ABVX Abstract #21
10
1,547
(20/n) $ABVX Abstract #20
7
1,404
(19/n) $ABVX Abstract #19
6
1,369
(18/n) $ABVX Abstract #18
9
1,541